Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.

Abstract	Persistent coinfection with the hepatitis B/D viruses (HDV) represents the most severe form of viral hepatitis. Hepatitis D often leads to liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma. The current treatment options are limited as only pegylated interferon-alpha (PEG-IFNa) has efficacy against HDV. However, treatment response is still unsatisfactory with 25-40% HDV RNA suppression after 1-2 years. In addition, late HDV RNA relapses have been described during long-term follow-up. Fortunately, new treatment options for patients with chronic hepatitis delta are now on the horizon. The hepatocyte entry inhibitor bulevirtide (formerly myrcludex B) and the farnesyl transferase inhibitor lonafarnib are currently explored in patients with chronic hepatitis delta in Phase 3 clinical studies. The nucleic acid inhibitor REP-2139-Ca and PEG-IFN-lambda are studied in Phase 2 trials. We here summarize data on the efficacy of these new antiviral drugs and the existing safety data on the treatment of HDV infection.
Authors	Katja Deterding, Heiner Wedemeyer
Journal	AIDS reviews (AIDS Rev) Vol. 21 Issue 3 Pg. 126-134 ( 2019) ISSN: 1698-6997 [Electronic] Spain
PMID	31532397 (Publication Type: Journal Article, Review)
Copyright	Copyright: © 2019 Permanyer.
Chemical References	Antiviral Agents Interferon-alpha Lipopeptides Nucleic Acids Piperidines Polymers Pyridines REP 2139 myrcludex-B lonafarnib
Topics	Antiviral Agents (administration & dosage, adverse effects) Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Coinfection (drug therapy) Drug-Related Side Effects and Adverse Reactions (epidemiology, pathology) Hepatitis B, Chronic (drug therapy) Hepatitis D (drug therapy) Hepatitis Delta Virus (drug effects) Humans Interferon-alpha (administration & dosage, adverse effects) Lipopeptides (administration & dosage, adverse effects) Nucleic Acids (administration & dosage, adverse effects) Piperidines (administration & dosage, adverse effects) Polymers (administration & dosage, adverse effects) Pyridines (administration & dosage, adverse effects) Recurrence Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!